List of Excipients in Branded Drug BICILLIN C-R 900/300

Bicillin C-R 900/300 Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Bicillin C-R 900/300 is a long-acting intramuscular suspension containing 900,000 units of benzathine penicillin G and 300,000 units of procaine penicillin G in a 2 mL dose. Its commercial value is tied less to active-ingredient exclusivity than to formulation control, suspension stability, prefilled delivery, manufacturing reliability, and regulatory substitution risk. The principal excipient platform includes lecithin, povidone, sodium citrate, polysorbate 80, sodium carboxymethylcellulose, and water for injection.[1]

The strongest commercial opportunities are differentiated injectable presentations, improved syringeability, robust particle-size control, supply-chain resilience, and authorized or generic alternatives that preserve the product's dual-depot pharmacokinetic profile.

What is Bicillin C-R 900/300 and how does its formulation work?

Bicillin C-R 900/300 is a sterile aqueous suspension for deep intramuscular administration. The product combines two penicillin G salts:

Component	Amount per 2 mL syringe	Functional role
Benzathine penicillin G	900,000 units	Poorly soluble depot component supporting prolonged exposure
Procaine penicillin G	300,000 units	More soluble component providing earlier release
Total penicillin activity	1.2 million units	Combined dose

The product is not an intravenous formulation. The label states that it must be administered by deep intramuscular injection and warns against inadvertent intravenous, intra-arterial, or nerve-adjacent administration.[1]

The formulation uses two penicillin salts with different solubility and release characteristics. Benzathine penicillin G forms the longer-acting depot. Procaine penicillin G contributes a comparatively faster-release fraction. The commercial formulation therefore depends on maintaining a reproducible suspension rather than merely dissolving the active ingredients.

What excipients are used in Bicillin C-R 900/300?

The labeled inactive ingredients are:

Excipient	Likely formulation function
Lecithin	Wetting, interfacial stabilization, and suspension support
Povidone	Dispersing and viscosity-modifying support
Sodium citrate	Buffering and ionic-environment control
Polysorbate 80	Wetting and interfacial stabilization
Sodium carboxymethylcellulose	Suspending agent and viscosity modifier
Water for injection	Aqueous vehicle

The public label identifies these ingredients but does not assign a separate quantitative concentration to each excipient.[1] Their combined purpose is to keep the penicillin particles uniformly dispersed, reduce settling and agglomeration, and permit withdrawal or injection through the intended needle system.

How does the Bicillin C-R excipient system affect product performance?

The commercial performance of Bicillin C-R depends on four linked properties: sedimentation, redispersibility, syringeability, and release behavior.

Suspension stability

Benzathine penicillin G and procaine penicillin G are suspended solids. The formulation must control particle settling during storage while still allowing the suspension to redisperse after handling. Sodium carboxymethylcellulose and povidone contribute to continuous-phase viscosity and particle suspension. Lecithin and polysorbate 80 support wetting and reduce interfacial instability.

A formulation that is too viscous can create injection-force problems. A formulation that is too fluid can settle rapidly and deliver nonuniform doses if the syringe is not adequately resuspended. The target is usually a controlled, mildly structured suspension with rapid redispersion under standardized shaking or inversion.

Particle-size control

Particle size is a critical quality attribute because it affects:

• Sedimentation rate
• Needle passage
• Injection force
• Depot surface area
• Dissolution rate
• Local tolerability
• Dose uniformity

A smaller particle-size distribution can improve suspension uniformity and dissolution but may increase aggregation, surface-area-driven degradation, or syringe resistance if the particles form dense networks. A broader or poorly controlled distribution can cause rapid settling and inconsistent depot behavior.

For a follow-on product, matching only the excipient names would not be sufficient. The sponsor would need to control particle-size distribution, polymorphic form, wetting state, suspension rheology, pH, osmolality, extractables, and release characteristics.

Syringeability and injection force

Bicillin C-R is administered as a relatively concentrated suspension. Syringeability is affected by:

• Needle gauge and length
• Suspension viscosity
• Particle agglomeration
• Syringe barrel dimensions
• Lubricant compatibility
• Storage temperature
• Resuspension procedure

Commercial differentiation could focus on lower injection force, improved dose delivery, reduced needle clogging, or a validated prefilled syringe that minimizes preparation errors. Any such change must preserve the labeled dose and administration route.

Depot release

Excipients can influence the local environment surrounding the suspended penicillin salts. They may affect wetting, sediment packing, redispersion, dissolution, and local residence time. A change that improves injection behavior could alter the release profile or tissue exposure.

This is the main formulation constraint. The objective is not simply to create a more convenient suspension. The product must maintain the clinical behavior associated with the benzathine/procaine combination.

What formulation patents protect Bicillin C-R 900/300?

The principal historic protection for Bicillin C-R is unlikely to be a currently meaningful patent barrier. The product is an established penicillin injection with a long commercial history, and any original composition or formulation patents would generally have expired decades ago.

The relevant intellectual-property risk is therefore more likely to arise from:

1. Manufacturing know-how for sterile suspension production.
2. Particle-size and milling controls.
3. Specific container-closure systems.
4. Prefilled syringe configurations.
5. Process controls for aseptic filling and resuspension.
6. Trade secrets involving raw-material specifications and hold times.
7. New-use or device patents, if separately developed.

The FDA label identifies Bicillin C-R under NDA 050627.[1] A current Orange Book review should be used to confirm any active listed patents or exclusivity entries associated with the NDA. The established product’s commercial defensibility is better characterized as a manufacturing and quality-control barrier than as a conventional patent moat.

Are method-of-use patents important for Bicillin C-R?

Method-of-use patents are unlikely to provide broad protection for the historical product. Penicillin G products have long-standing uses in susceptible bacterial infections, including streptococcal infections and syphilis-related treatment protocols.

A new method-of-use strategy could be relevant only if it involved a distinct, patent-eligible clinical regimen, patient population, dosing schedule, or combination therapy. Such protection would not automatically block a generic manufacturer from marketing the product for non-patented uses, particularly where the generic label could use a carved-out indication.

What is the FDA regulatory status of Bicillin C-R 900/300?

Bicillin C-R 900/300 is an FDA-approved prescription injectable drug marketed by Pfizer under NDA 050627.[1] It is a conventional small-molecule drug, not a biologic. Biosimilar regulation under the Public Health Service Act is therefore not the relevant pathway.

How would a generic company challenge Bicillin C-R?

A potential generic would normally evaluate an abbreviated new drug application pathway, subject to FDA requirements for injectable suspensions. The challenge is more complex than a simple aqueous solution because the applicant must demonstrate pharmaceutical equivalence and adequate performance of a particulate depot system.

The relevant development package would likely include:

• Same active ingredients and strengths
• Same dosage form and route
• Comparable inactive-ingredient profile
• Particle-size distribution
• Solid-state and polymorph characterization
• pH and osmolality
• Redispersibility
• Injectability and syringeability
• In vitro release data
• Stability data
• Sterility and endotoxin control
• Container-closure compatibility
• Comparative pharmacokinetic or clinical evidence where required

A Paragraph IV certification would be relevant only if the Orange Book contained an unexpired patent listed for the reference product. The public product label alone does not establish a current Paragraph IV barrier.[1][2]

What commercial opportunities exist in Bicillin C-R excipients?

1. Improved prefilled syringe performance

A ready-to-use syringe can reduce preparation time, dosing errors, and occupational handling. The commercial opportunity is strongest where the device improves:

• Resuspension consistency
• Injection-force control
• Needle compatibility
• Dose visibility
• Label readability
• Administration workflow

The device must tolerate the suspension over its full shelf life without excessive adsorption, silicone interaction, plunger sticking, or particle settling that cannot be corrected by the labeled handling procedure.

2. Excipient optimization for redispersibility

A follow-on manufacturer could evaluate alternative grades of povidone, polysorbate 80, lecithin, or carboxymethylcellulose. The opportunity is not necessarily to replace the excipients. It may be to optimize:

• Molecular-weight distribution
• Viscosity grade
• Surfactant purity
• Fatty-acid composition of lecithin
• Peroxide and aldehyde limits
• Microbial burden
• Raw-material lot consistency

The formulation must avoid changing the clinical release profile. A lower-cost excipient is commercially useful only if it produces equivalent stability and injectability.

3. Supply-chain substitution

Supply continuity is a material opportunity because sterile penicillin products are vulnerable to shortages involving active pharmaceutical ingredient supply, aseptic capacity, specialized filling lines, and quality-release delays.

A second-source excipient strategy could reduce dependence on a single supplier for:

• Pharmaceutical-grade polysorbate 80
• Lecithin
• High-purity povidone
• Sodium carboxymethylcellulose
• Sterile water and packaging components

Each alternate supplier would require qualification, comparability testing, and regulatory assessment. Changes to animal-derived or plant-derived raw materials may also affect traceability, impurity control, and regulatory documentation.

4. Reduced injection burden

An excipient and device platform that lowers injection force could improve administration in outpatient, pediatric, or high-throughput settings. The opportunity is commercially meaningful but technically constrained because lower viscosity can increase sedimentation, while higher viscosity can worsen injection force.

The practical target is a balanced rheology profile rather than maximum viscosity or maximum fluidity.

5. New packaging configurations

Potential commercial formats include:

• Single-dose prefilled syringes
• Unit-dose cartons with administration accessories
• Tamper-evident presentations
• Cold-chain-optimized packaging
• Institutional multipacks
• Packaging with clearer resuspension instructions

Packaging improvements do not necessarily create strong patent protection, but they can support contracting, procurement, and brand differentiation.

How strong is the generic-entry risk for Bicillin C-R?

Generic-entry risk is moderate from a patent perspective but potentially lower in practice because of technical and commercial barriers.

Risk factor	Assessment
Active-ingredient patent barrier	Low for the historic product
Formulation patent barrier	Likely limited unless newer patents are listed
FDA development complexity	Moderate to high
Sterile manufacturing difficulty	High
Suspension characterization burden	High
Market size	Specialized but clinically important
Shortage-driven opportunity	Potentially significant
Pricing power	Constrained by procurement and generic competition
Biosimilar risk	Not applicable

A generic could face a relatively open patent field while still requiring substantial investment in sterile injectable manufacturing, analytical development, device qualification, and clinical or pharmacokinetic bridging.

How does Bicillin C-R compare with Bicillin L-A?

Attribute	Bicillin C-R 900/300	Bicillin L-A
Active ingredients	Benzathine penicillin G plus procaine penicillin G	Benzathine penicillin G
Dose discussed	1.2 million units per 2 mL	Product-specific benzathine penicillin G dose
Release concept	Mixed faster and longer depot components	Primarily long-acting benzathine depot
Formulation complexity	Higher because two penicillin salts must remain controlled	Lower in active-component count
Substitution	Not automatically interchangeable	Not automatically interchangeable
Regulatory risk	Must preserve dual-component performance	Must preserve benzathine-only performance

Bicillin C-R should not be treated as a simple lower-strength or interchangeable version of Bicillin L-A. The active-ingredient composition and release behavior differ. A commercial strategy based on excipient optimization must preserve the specific dual-salt product profile.

What manufacturing and IP barriers affect commercial entry?

The most important barriers are process-based:

1. Consistent API particle engineering.
2. Controlled wetting and dispersion.
3. Aseptic suspension compounding.
4. Uniform filling of a settling suspension.
5. Validated resuspension after storage.
6. Sterility assurance for a viscous particulate product.
7. Reliable syringe and needle performance.
8. Long-term stability under labeled storage conditions.
9. Raw-material qualification and change control.
10. Demonstration that formulation changes do not alter release.

Trade-secret protection may be stronger than patent protection in these areas. A competitor can legally reproduce the labeled excipient list while still lacking the process parameters needed to produce a robust commercial product.

What are the most attractive commercial strategies?

The highest-value strategies are:

• Launching an authorized or generic equivalent with reliable supply.
• Developing a prefilled syringe with validated low injection force.
• Improving redispersion without changing pharmacokinetics.
• Establishing dual-source excipient and API supply.
• Using advanced particle-size controls to reduce batch variability.
• Targeting institutional procurement with shortage-resilient packaging.
• Building a manufacturing platform applicable to other depot penicillin suspensions.

A reformulation that changes the active ratio, release profile, or route would face substantially greater regulatory risk. An incremental strategy focused on delivery, stability, and supply reliability is more commercially practical.

Key Takeaways

• Bicillin C-R 900/300 contains 900,000 units of benzathine penicillin G and 300,000 units of procaine penicillin G per 2 mL.
• Its excipient system includes lecithin, povidone, sodium citrate, polysorbate 80, sodium carboxymethylcellulose, and water for injection.
• The central formulation challenge is controlling sedimentation, redispersibility, syringeability, and depot release at the same time.
• Historical patent protection is unlikely to be the principal barrier. Manufacturing know-how and sterile suspension capability are more important.
• Biosimilar competition is not relevant because Bicillin C-R is a conventional small-molecule drug.
• Generic entry would likely require significant analytical and manufacturing work because the product is a particulate injectable suspension.
• The strongest opportunities are supply continuity, prefilled delivery, improved injection performance, excipient-source qualification, and process reproducibility.
• Bicillin C-R and Bicillin L-A are not automatically interchangeable because they contain different active-ingredient combinations.

FAQs

Can Bicillin C-R excipients be replaced without conducting clinical studies?

Potentially, but the regulatory burden depends on the nature and extent of the change. A replacement excipient that alters particle wetting, suspension rheology, depot release, or local tolerability could require substantial comparative evidence.

Is polysorbate 80 essential to the Bicillin C-R formulation?

The label identifies polysorbate 80 as an inactive ingredient, but the public label does not establish that it is technically indispensable. Any removal or replacement would require evidence that suspension stability, injectability, particle behavior, and release remain comparable.

Can Bicillin C-R be reformulated as a ready-to-use liquid solution?

A true solution would not be a straightforward reformulation because the product relies on poorly soluble penicillin salts and depot behavior. Converting it to a solution would likely change release characteristics and require a new product-development strategy.

Does a generic Bicillin C-R need to use the same excipients?

Not necessarily. A generic may use different inactive ingredients if FDA requirements for pharmaceutical equivalence, safety, performance, and labeling are satisfied. For a complex suspension, excipient changes can materially increase development risk.

What is the most defensible patent strategy for a follow-on Bicillin C-R product?

The strongest new protection would likely focus on a validated device-formulation combination, defined particle-size and rheology specifications, a novel stabilizing system, or a manufacturing process that produces a measurable performance advantage.

References

1. Pfizer Inc. (n.d.). Bicillin C-R 900/300: Prescribing information. U.S. Food and Drug Administration labeling database.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2016). Product-specific guidances for generic drug development.
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.